Maria E. Cabanillas, MD

Dr Cabanillas reviews updated data that was recently presented at the American Thyroid Association conference on the use of larotrectinib in patients with advanced TRK fusion positive thyroid cancer.

Maria E. Cabanillas, MD, an oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses how to deliver the optimal surgical approach to patients with medullary thyroid cancer.

Maria E. Cabanillas, MD, oncologic endocrinologist, tenured professor and the faculty director of clinical research in the department of Endocrine Neoplasia at The University of Texas MD Anderson Cancer Center, discusses current systemic treatments in medullary thyroid cancer, along with the potential for peptide receptor radionuclide therapy.

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

The role of BRAF inhibitors and checkpoint inhibitors in differentiated thyroid cancer, and potential considerations for using BRAF inhibition as redifferentiation therapy.

The rationale for targeting actionable mutations in differentiated thyroid cancer with RET and NTRK inhibitors.

Considerations regarding approaches to sequencing therapies for differentiated thyroid cancer.

An overview of the types of targeted drug classes available to treat differentiated thyroid cancer at various clinical stages.

Maria E. Cabanillas, MD, describes what triggers her to initiate therapy for differentiated thyroid cancer and variables that impact treatment choice.

Maria E. Cabinillas, MD, associate professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses administering lenvatinib (Lenvima) as a first-line therapy for patients with differentiated thyroid cancer (DTC).